To study whether there was a correlation between specific systemic T‐cell subsets and responses to anti‐PD‐L1/PD‐1 immunotherapy in NSCLC patients, a prospective study was carried out in a cohort of 51 patients treated with PD‐L1/PD‐1 inhibitors (Table EV1). Here, CD274 is linked to non-small cell lung carcinoma.